PFE vs VRT: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Vertiv Holdings Co · Industrials
$333.05
-45.0% upside to fair value
Grade D High Quality
QuantHub Verdict
PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE VRT
Current Price $25.22 $333.05
Fair Value Estimate $25.92 $183.18
Upside to Fair Value +2.8% -45.0%
Market Cap $143.7B $127.9B
Forward P/E 19.2x 81.8x
EV / EBITDA 12.3x 55.4x
Price / Sales 2.3x 11.8x
Price / FCF 15.2x 55.4x
Revenue Growth YoY +5.4% +30.1%
Gross Margin 69.3% 36.2%
Operating Margin 23.4% 18.5%
Return on Equity 8.4% 42.1%
Dividend Yield 0% 0%
FCF Yield 6.6% 1.81%
Analyst Consensus Hold Strong Buy
Investment Thesis
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
VRT — Vertiv Holdings Co
Vertiv Holdings Co operates in the industrials sector, specializing in electrical equipment and parts with a strong focus on data center critical infrastructure. The company benefits from a durable competitive position supported by a broad product portfolio that drives approximately 75% of sales from data centers. Vertiv's business quality is high, demonstrated by a 42.1% return on equity, strong…
Accumulation Zones
Metric PFE VRT
Zone Low $19.44 $137.38
Zone High $22.03 $155.70
In Buy Zone? No No
← PFE Research    VRT Research →    All Research